When Good Is Not Good Enough: Revisiting Intralesional Therapy for Keloids

Q: What does this research mean for the field?

Current intralesional therapies for keloids may be inadequate and require reevaluation to achieve optimal clinical outcomes. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Sushmitha Dharani Sankar

doi:10.1111/ijd.70635

August 18, 2026International Journal of DermatologyOpen Access

When Good Is Not Good Enough: Revisiting Intralesional Therapy for Keloids

View Full Paper

Ask AI

Bookmark

Share

Key Points

To review the therapeutic efficacy, limitations, and clinical outcomes of intralesional therapies for keloid management.
Expert clinical commentary reviewing standard intralesional pharmacotherapies and injection protocols used for treating keloid lesions.
Conventional intralesional monotherapies often provide partial clinical regression but carry notable recurrence rates and treatment resistance.
Optimizing injection protocols and incorporating multimodal or combination therapies are essential to improve long-term lesion resolution.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Clinical commentary evaluates intralesional therapies in keloid patients, highlighting the need for improved scar management strategies.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sushmitha Dharani Sankar (2026) studied this question.

synapsesocial.com/papers/6a86b5b08a91293e6a1cd2a2 https://doi.org/10.1111/ijd.70635

View Full Paper

Ask AI

Bookmark

Share

When Good Is Not Good Enough: Revisiting Intralesional Therapy for Keloids

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

When Good Is Not Good Enough: Revisiting Intralesional Therapy for Keloids

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading